Recently, Anhui Bocompounds Pharmaceutical Co., Ltd received the "Approval Notice for Marketing Application of Chemical Raw Material Potassium" from the National Medical Products Administration (NMPA) regarding its chemical raw material drug, Azilsartan Potassium.

Azilsartan Potassium is an oral prodrug that rapidly hydrolyzes in the body to the active ingredient azilsartan. It selectively blocks the binding of the angiotensin domain to the AT1 receptor, inhibiting vasoconstriction and aldosterone secretion, thereby achieving an antihypertensive effect. In November 2024, Jianfeng Beika's application for technical review of Azilsartan Potassium raw material was accepted by the NMPA's Center for Drug Evaluation, and it recently received the "Approval Notice for Marketing Application of Chemical Raw Material Drug" from the NMPA.

As a core raw material in the next-generation antihypertensive field, Azilsartan Potassium, with its stable antihypertensive effect and outstanding cardio-renal protective effect, has become a key raw material for clinical hypertension treatment. This approval not only completes the high-end API product system of Peak North Carolina, but also fills the supply gap of related categories in China, providing downstream formulation companies with cost-effective domestic solutions.